Thalidomide-O-C4-COOH is primarily utilized in research and development within the pharmaceutical industry, particularly in the study of targeted drug delivery systems. Its structure allows it to act as a linker or conjugate in the design of prodrugs, enabling the attachment of therapeutic agents to enhance their specificity and efficacy. This compound is often explored in the context of cancer therapy, where it can be used to modify the pharmacokinetics and biodistribution of anticancer drugs, potentially reducing off-target effects and improving treatment outcomes. Additionally, it is investigated for its role in immunomodulation, particularly in conditions where selective inhibition of inflammatory pathways is required. Researchers also study its potential in creating more stable and bioavailable drug formulations, contributing to advancements in personalized medicine.